VV116 is an oral antiviral drug candidate developed to treat COVID-19. It is a nucleoside analog that inhibits the replication of the SARS-CoV-2 virus by targeting its RNA-dependent RNA polymerase, helping reduce viral load and disease severity. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Deuremidevir, Mindeudesivir and Mindavi. Its PubChem CID is 163358784.
VV116
| CAS No | 2647442-33-7 |
|---|---|
| Molecular Formula | C24H31N5O7 |
| Molecular Weight | 502.5 g/mol |
| Synonyms | [(2R,3R,4R,5R)-5-(4-amino-5-deuteriopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-bis(2-methylpropanoyloxy)oxolan-2-yl]methyl 2-methylpropanoate |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
VV116 is an oral antiviral drug candidate developed to treat COVID-19. It is a nucleoside analog that inhibits the replication of the SARS-CoV-2 virus by targeting its RNA-dependent RNA polymerase, helping reduce viral load and disease severity.
The listed CAS number is 2647442-33-7.
The listed molecular formula is C24H31N5O7.
The listed molecular weight is 502.5 g/mol.
[(2R,3R,4R,5R)-5-(4-amino-5-deuteriopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-bis(2-methylpropanoyloxy)oxolan-2-yl]methyl 2-methylpropanoate.
The source lists Deuremidevir, Mindeudesivir and Mindavi.